Horizon Therapeutics Public Limited Company Peer Comparison
Metric | Value | Ranking | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $26.6 Billion | 12/12 | LLY $828.7B |
JNJ $373.8B |
ABBV $341.1B |
AZN $230.8B |
MRK $216.7B |
NVS $211.3B |
AMGN $158.6B |
GILD $128.8B |
SNY $124.1B |
BMY $113.9B |
GSK $75.4B |
HZNP $26.6B |
Gross Margin | 77% | 3/12 | LLY 82% |
MRK 80% |
HZNP 77% |
AZN 77% |
BMY 75% |
NVS 75% |
GSK 74% |
ABBV 71% |
JNJ 70% |
SNY 68% |
AMGN 61% |
GILD -100% |
Profit Margin | 13% | 7/12 | AMGN 33% |
LLY 33% |
NVS 21% |
MRK 19% |
GILD 17% |
GSK 15% |
HZNP 13% |
JNJ 12% |
ABBV 11% |
AZN 11% |
SNY 11% |
BMY 10% |
EBITDA margin | 15% | 11/12 | ABBV 49% |
LLY 45% |
BMY 38% |
NVS 38% |
GSK 33% |
JNJ 32% |
AZN 30% |
SNY 26% |
MRK 25% |
AMGN 24% |
HZNP 15% |
GILD 12% |
Quarterly Revenue | $945.0 Million | 12/12 | SNY $23.3B |
JNJ $22.5B |
MRK $16.7B |
ABBV $14.5B |
AZN $13.6B |
NVS $13.6B |
LLY $13.5B |
BMY $11.9B |
GSK $10.1B |
AMGN $8.5B |
GILD $7.6B |
HZNP $945.0M |
Quarterly Earnings | $127.1 Million | 12/12 | LLY $4.4B |
MRK $3.2B |
AMGN $2.8B |
NVS $2.8B |
JNJ $2.7B |
SNY $2.5B |
ABBV $1.6B |
GSK $1.5B |
AZN $1.4B |
GILD $1.3B |
BMY $1.2B |
HZNP $127.1M |
Quarterly Free Cash Flow | $291.8 Million | 9/12 | MRK $8.5B |
BMY $5.3B |
ABBV $5.2B |
GILD $4.5B |
AMGN $3.3B |
NVS $3.1B |
AZN $2.0B |
GSK $564.1M |
HZNP $291.8M |
JNJ -$0 |
LLY -$0 |
SNY -$553.8M |
Trailing 4 Quarters Revenue | $3.6 Billion | 12/12 | JNJ $87.7B |
SNY $74.6B |
MRK $63.2B |
ABBV $55.5B |
AZN $51.2B |
NVS $50.7B |
BMY $47.4B |
LLY $45.0B |
GSK $40.3B |
AMGN $32.5B |
GILD $28.3B |
HZNP $3.6B |
Trailing 4 Quarters Earnings | $438.0 Million | 10/12 | SNY $23.3B |
JNJ $22.5B |
MRK $16.7B |
ABBV $14.5B |
AZN $13.6B |
NVS $13.6B |
LLY $13.5B |
BMY $11.9B |
GSK $10.1B |
AMGN $8.5B |
GILD $7.6B |
HZNP $945.0M |
Quarterly Earnings Growth | 108% | 1/12 | HZNP 108% |
LLY 101% |
AMGN 64% |
SNY 57% |
AZN 4% |
ABBV -12% |
GSK -28% |
MRK -33% |
BMY -37% |
GILD -43% |
NVS -67% |
JNJ -90% |
Annual Earnings Growth | -35% | 8/12 | LLY 425% |
MRK 192% |
SNY 6% |
AZN -5% |
NVS -13% |
AMGN -28% |
GSK -34% |
HZNP -35% |
ABBV -35% |
JNJ -65% |
GILD -98% |
BMY -189% |
Quarterly Revenue Growth | 8% | 7/12 | SNY 99% |
LLY 45% |
AMGN 23% |
AZN 18% |
NVS 15% |
GSK 10% |
HZNP 8% |
BMY 8% |
GILD 7% |
JNJ 5% |
ABBV 4% |
MRK 4% |
Annual Revenue Growth | 3% | 9/12 | SNY 57% |
LLY 19% |
AMGN 17% |
GSK 12% |
AZN 12% |
BMY 6% |
NVS 6% |
GILD 5% |
HZNP 3% |
MRK 3% |
ABBV 0% |
JNJ -10% |
Cash On Hand | $2.5 Billion | 9/12 | MRK $14.6B |
NVS $11.5B |
AMGN $9.0B |
BMY $7.9B |
SNY $7.5B |
ABBV $7.3B |
AZN $4.8B |
GSK $3.8B |
HZNP $2.5B |
GILD -$0 |
JNJ -$0 |
LLY -$0 |
Short Term Debt | $16.0 Million | 9/12 | ABBV $12.6B |
SNY $10.5B |
NVS $8.3B |
GSK $4.3B |
AMGN $3.5B |
MRK $3.1B |
AZN $1.6B |
BMY $1.1B |
HZNP $16.0M |
GILD -$0 |
JNJ -$0 |
LLY -$0 |
Long Term Debt | $2.5 Billion | 9/12 | ABBV $58.5B |
AMGN $56.9B |
BMY $48.7B |
MRK $35.0B |
AZN $30.0B |
NVS $22.9B |
GSK $17.4B |
SNY $13.7B |
HZNP $2.5B |
GILD $0 |
JNJ $0 |
LLY $0 |
PE | 60.74 | 4/12 | GILD 1021.84 |
LLY 78.26 |
ABBV 66.51 |
HZNP 60.74 |
AMGN 37.50 |
AZN 35.54 |
JNJ 25.46 |
MRK 17.84 |
NVS 17.70 |
GSK 14.58 |
SNY 14.35 |
BMY -1.00 |
PS | 7.30 | 2/12 | LLY 18.40 |
HZNP 7.30 |
ABBV 6.14 |
AMGN 4.88 |
GILD 4.55 |
AZN 4.51 |
JNJ 4.26 |
NVS 4.17 |
MRK 3.43 |
BMY 2.40 |
SNY 1.51 |
GSK 1.46 |
PB | 5.01 | 7/12 | LLY 57.87 |
ABBV 56.18 |
AMGN 21.07 |
BMY 6.62 |
AZN 5.66 |
JNJ 5.23 |
HZNP 5.01 |
MRK 4.86 |
NVS 4.79 |
GSK 4.27 |
GILD 3.01 |
SNY 1.55 |
PC | 10.79 | 9/12 | AZN 48.12 |
ABBV 47.00 |
GSK 19.86 |
NVS 18.44 |
AMGN 17.60 |
SNY 16.62 |
MRK 14.85 |
BMY 14.43 |
HZNP 10.79 |
GILD -1.00 |
JNJ -1.00 |
LLY -1.00 |
Liabilities to Equity | 0.75 | 9/12 | ABBV 22.77 |
AMGN 11.07 |
BMY 4.46 |
GSK 3.08 |
MRK 1.64 |
AZN 1.57 |
NVS 1.32 |
SNY 0.78 |
HZNP 0.75 |
GILD 0.00 |
JNJ -1.00 |
LLY -1.00 |
ROA | 0.05 | 6/12 | NVS 12% | MRK 10% | GSK 9% | SNY 7% | AZN 6% | HZNP 5% | AMGN 5% | ABBV 4% | GILD 0% | BMY -8% | JNJ -100% | LLY -100% |
ROE | 0.08 | 10/12 | ABBV 85% |
LLY 74% |
AMGN 56% |
GSK 36% |
MRK 27% |
NVS 27% |
JNJ 21% |
AZN 16% |
SNY 12% |
HZNP 8% |
BMY -42% |
GILD -100% |
Current Ratio | 2.33 | 2/12 | GILD 4.65 |
HZNP 2.33 |
SNY 2.29 |
NVS 1.76 |
AZN 1.64 |
MRK 1.61 |
GSK 1.31 |
BMY 1.22 |
AMGN 1.09 |
ABBV 1.04 |
JNJ 0.00 |
LLY 0.00 |
Quick Ratio | 0.62 | 1/12 | GILD 1021.84 |
LLY 78.26 |
ABBV 66.51 |
HZNP 60.74 |
AMGN 37.50 |
AZN 35.54 |
JNJ 25.46 |
MRK 17.84 |
NVS 17.70 |
GSK 14.58 |
SNY 14.35 |
BMY -1.00 |
Long Term Debt to Equity | 0.48 | 8/12 | ABBV} 9.70 |
AMGN} 7.55 |
BMY} 2.84 |
GSK} 0.94 |
MRK} 0.79 |
AZN} 0.74 |
NVS} 0.52 |
HZNP} 0.48 |
SNY} 0.17 |
JNJ} 0.00 |
LLY} 0.00 |
GILD} -1.00 |
Debt to Equity | 0.48 | 8/12 | ABBV 11.78 |
AMGN 8.02 |
BMY 2.90 |
GSK 1.18 |
MRK 0.86 |
AZN 0.78 |
NVS 0.71 |
HZNP 0.48 |
SNY 0.33 |
JNJ 0.00 |
LLY 0.00 |
GILD -1.00 |
Burn Rate | -115.10 | 12/12 | NVS 63.53 |
AZN 29.40 |
AMGN 27.29 |
SNY 16.54 |
BMY 7.85 |
ABBV 1.85 |
GILD 0.00 |
JNJ 0.00 |
LLY 0.00 |
MRK -15.04 |
GSK -24.84 |
HZNP -115.10 |
Cash to Cap | 0.09 | 1/12 | HZNP 0.09 |
BMY 0.07 |
MRK 0.07 |
AMGN 0.06 |
SNY 0.06 |
GSK 0.05 |
NVS 0.05 |
ABBV 0.02 |
AZN 0.02 |
GILD 0.00 |
JNJ 0.00 |
LLY 0.00 |
CCR | 2.30 | 5/12 | BMY 4.35 |
GILD 3.63 |
ABBV 3.33 |
MRK 2.69 |
HZNP 2.30 |
AZN 1.42 |
AMGN 1.17 |
NVS 1.09 |
GSK 0.38 |
JNJ 0.00 |
LLY 0.00 |
SNY -0.22 |
EV to EBITDA | 186.89 | 1/12 | HZNP} 186.89 |
GILD} 144.99 |
LLY} 134.78 |
AMGN} 102.58 |
AZN} 62.79 |
MRK} 58.74 |
ABBV} 57.49 |
JNJ} 52.65 |
NVS} 44.55 |
GSK} 42.17 |
BMY} 34.02 |
SNY} 28.23 |
EV to Revenue | 7.33 | 2/12 | LLY 18.40 |
HZNP 7.33 |
ABBV 7.29 |
AMGN 6.46 |
AZN 5.03 |
NVS 4.56 |
GILD 4.55 |
JNJ 4.26 |
MRK 3.80 |
BMY 3.28 |
GSK 2.74 |
SNY 2.06 |